Genestrings Labs: From a Vision for Accessible Genetics to a New Era of Precision Diagnostics

Healthcare is evolving and moving from detecting diseases to treating it as it appears to understand the risk, identify disease earlier, and use individual biological information to guide clinical decisions. At the centre of this transformation is genetic and molecular diagnostics-an area that has evolved rapidly over the past few decades.

Recognizing the potential of genetics to transform the way healthcare is delivered in India, Dr. Gauri Agarwal and her team have envisioned Genestrings as a platform that can make advanced molecular and genetic testing more accessible, reliable, and clinically meaningful. What began as a focus on bringing high-end genetic testing to India has moved closer to the patients and has evolved into a broader diagnostic ecosystem that offers services across reproductive genetics, prenatal testing, inherited disorders, cancer genetics, newborn screening, and customized medicine. Today, Genestrings' stated objective is to understand and meet the evolving requirements of genetic testing in India, supported by an in-house laboratory and advanced diagnostic technologies.

A Vision Born from the Need for Better Answers

Genetic disorders and inherited conditions require answers that a conventional diagnostic approach may not provide. For couples facing infertility or recurrent pregnancy loss, families with a history of inherited disease, parents concerned about genetic conditions in their children, or patients who are dealing with hereditary cancers, understanding the genetic basis of the condition plays a crucial role in clinical decision-making

The vision behind Genstrings was to bridge this gap between advanced genetic science and practical healthcare. Rather than treating genetics as a specialized service available only to a limited segment of the population, the organization sought to build an ecosystem where genetic testing can become a more accessible part of reproductive and clinical healthcare.

The philosophy is reflected in Genestrings' current portfolio that covers genetic services across different phases of life, which includes pre-conception and pregnancy to childhood, adulthood, cancer care, and personalized medicine.

Building India's Genetic Diagnostics Ecosystem

Genestrings has developed its capabilities around multiple areas of genetic and molecular testing. Its current services include prenatal genetic testing, pre-conception and carrier screening, newborn screening, inherited and paediatric disorder testing, somatic cancer testing, transplant-related HLA typing, and pharmagenomics.

The breadth of these services reflects an enormous shift in modern healthcare. Genetic testing is no longer limited to diagnosing rare inherited diseases. It will also contribute to family planning, reproductive decision-making, cancer risk assessment, treatment planning and the understanding of individual disease risks. For Genestrings, this has meant investing in laboratory capabilities that will support increasingly difficult forms of testing.

The organization recently lists Next Generation Sequencing platforms, microarray technology, Sanger sequencing, RT-PCR systems and GeneXpert technology among its laboratory infrastructure.

A Defining Chapter during the COVID-19 Pandemic

The COVID-19 pandemic became an unexpected test of diagnostic infrastructure across the globe. As India faced unprecedented demand for molecular testing, laboratories were required to scale rapidly while maintaining accuracy, turnaround times and operational reliability.

Genestrings became part of this crucial diagnostic response. Its laboratory at Delhi’s Indira Gandhi International Airport conducted COVID-19 testing for travelers during the pandemic. In January 2021, The Times of India reported that the laboratory had begun offering rapid antigen testing at the airport and had already tested more than 250 passengers in an early pilot for international travelers.

This is one of the most significant milestones that came in October 2021. The Canadian government appointed the Genestrings laboratory at Delhi International Airport as the sole COVID-19 testing facility in India for eligible passengers travelling directly to Canada from India, under the testing requirements then in force. The laboratory provided molecular testing and reports with QR codes for the travelers within the specified pre-departure window. For an Indian diagnostic organization, the recognition represented a vital validation of its testing infrastructure and operational capabilities at a time when accuracy and turnaround time were crucial.

From Pandemic Testing to Precision Healthcare

The end of the pandemic does not mark the end of Genestrings' diagnostic journey. Instead, the experience reinforced the crucially of advanced molecular diagnostics and strengthened the organization’s broader focus on genetics. Today Genestrings' work extends far beyond infectious disease testing.

Its reproductive genetics portfolio addresses areas that include infertility, recurrent pregnancy loss and unexplained pregnancy or neonatal outcomes. The laboratory also provides testing for paediatric disorders, which includes thalassemia, sickle cell disease, spinal muscular atrophy and Duchenne muscular dystrophy. In oncology, the services encompasses hereditary ovarian and breast cancer testing as well as somatic testing intended to support precision treatment approaches. This expansion reflects the organization’s broader vision by using genetics not only to diagnose disease but to support prevention and personalized healthcare.

Making Advanced Testing More Accessible

one of the challenges in genetic medicine is accessibility. Advanced genetic tests can be technically difficult and need specialized laboratory infrastructure, trained professionals and appropriate clinical interpretation. Genestrings has sought to address this difficulty through an integrated model combining laboratory technology with genetic consultation and home sample collection. Its current platform provides doorstep blood sample collection and highlights secure handling of patient information alongside access to an in-house laboratory and genetic consultation. The objective is to reduce some of the practical barriers that patients might encounter when accessing specialized diagnostic services. For patients, this means that sophisticated testing does not necessarily have to involve navigating various disconnected facilities. Despite this, testing, laboratory processing and consultation can be coordinated within the connected diagnostic ecosystem.

Technology as an Enabler, Not the Destination

For Genestrings, technology forms the foundation of the diagnostic capabilities, but the larger purpose is clinical utility. Next Generation Sequencing, microarray analysis and Sanger sequencing can generate a huge amount of genetic information. The challenge is now translating that information into results that patients and clinicians can understand and use appropriately. This makes genetic counselling and specialist expertise a crucial part of the diagnostic process.

Genestrings' current model therefore combines laboratory technology with clinical evaluation and genetic consultation, with the stated aim of supporting informed healthcare decisions.  

A Broader Vision for Indian Healthcare

The journey of Genestrings reflects a wider transformation taking place within Indian healthcare. As awareness of genetic disorders, inherited cancer risks and personalized medicine increases, the demand for sophisticated diagnostic capabilities is also growing. The vision of the organization contributes to the transition by making an advanced genetic testing more accessible and by integrating genetics into mainstream healthcare. The journey from building specialized genetic diagnostic capabilities in becoming the part of one of the largest pandemic testing operations and subsequently expanding to the wider genetics and precision diagnostics portfolio illustrates how diagnostic healthcare can evolve in response to the changing patient requirements.

Looking Ahead

The future of diagnostics is expected to move rapidly towards earlier detection, risk prediction, personalized treatment and prevention.

Genestrings is positioning itself within the changing landscape by expanding its work across reproductive genetics, inherited disorders, oncology, newborn screening and personalized medicine.

For Dr. Gauri Agarwal and the team behind Genestrings, the larger objective is to make genetic information more accessible and useful to the people who need it. The journey that began with a vision for accessible genetic testing has therefore grown into something broader–a diagnostic platform which is built around the belief that understanding a person’s biology will help healthcare become more informed, more precise and more personalized.

Genestrings story is not simply about making a laboratory; it is about building access to the information that will help doctors, families and individuals to make better-informed healthcare decisions. As genetics continues to reshape medicine, that vision places Genestrings at the intersection of technology, science and patient-centered healthcare.